Mental illness is the real pandemic.
This silent curse is a plague on society.
As the stresses of modern life intensify, more and more people are struggling to keep up.
Yet despite this global crisis, medicinal science has failed to develop effective forms of treatment.
The problem has become so acute that mental illness is now widely recognized as one of the primary causes of poor health and disability worldwide.
Find this hard to believe?
Well, according to the World Health Organization, one in four of the population has a psychological disorder of some description.
That is a huge number of people. The likelihood is that your life has been touched in some way by mental illness, whether or directly or indirectly.
Depression in particular is on the rise.
This condition can be an especially heavy burden to bear, not least because traditional medicines and treatments have such poor rates of success.
Living with depressive illness can have a devastating effect on relationships, work performance and the ability to live a fulfilling life.
Sufferers can often feel isolated and hopeless, abandoned by a healthcare system that has failed to provide them with the healing they need.
The drugs are too slow to act, the side effects can be horrendous and the odds of a long-term cure are low.
However, this could all be about to change dramatically.
Champignon Brands (CSE:SHRM│OTC:SHRMF) is pioneering a radical new approach to treating depression and other mental health conditions. The company is combining a rigorous scientific approach with innovative clinical therapy and an unusual vital ingredient.
Champignon Brands (CSE:SHRM│OTC:SHRMF) is pursuing the most effective approach to treating depression successfully, right now.
As many as 300 million people live with depression on this planet. Millions more suffer from conditions such as PTSD and substance abuse disorders.
This may shock you to learn, but research from the Mental Health Foundation suggests that as many as one in five adults has considered taking their own lives at some point.
The numbers are alarming and the human cost appalling.
Regrettably, as it stands, fewer than 45% of patients suffering from depression respond positively to traditional antidepressants.
When these drugs do work, they can take up to six weeks to act and the side effects can be worse than the initial diagnosis. Thanks to their addictive nature, coming off antidepressants is very difficult.
And this even assumes that the patient is able to get this far – World Health Organization stats show that approximately 50% do not take their medications as prescribed.
It is no wonder that long-term success rates for patient cure using antidepressants can be as low as 10-15%.
For those who are saddled with the millstone of depression, the prospect of full recovery can feel out of reach.
The mountain appears too steep to climb.
However, this bad situation is improving, and it is improving fast.
Champignon Brands’ (CSE:SHRM│OTC:SHRMF) research into revolutionary new drugs and treatment method is delivering momentous results, with as much as 60% efficacy with its current treatment protocols.
That’s right.
60% effectiveness!
When you consider that the global antidepressants market is expected to be worth $28.6 billion in 2020, (a colossal waste of vital resources based on how ineffective they can be) this presents a huge opportunity for Champignon Brands (CSE:SHRM│OTC:SHRMF).
The surprising secret ingredient to Champignon Brands’ (CSE:SHRM│OTC:SHRMF) success
A significant proportion of Champignon Brands’ (CSE:SHRM│OTC:SHRMF) scientific treatment approach is focussed on a novel and research-driven chemical compound.
Ketamine.
It turns out that ketamine is an extremely effective psychotherapeutic and is now poised to rock the foundations of mental health treatment.
There has been a lot of scientific speculation about ketamine’s potential to act as a mental healing agent since the 1960s.
In recent years, this has culminated in robust research projects, with tens of millions of dollars having been spent on the investigation and validation of ketamine’s value and safety as a “psycho-therapeutic medicine”.
World-class research institutions like John Hopkins University and Yale have been at the vanguard of this new frontier of medicinal science.
The results have been extremely encouraging, and a long list of successful research is being collated at an astonishing pace.
When administered carefully and in the correct dosages, ketamine-based psychotherapeutic medicines can almost instantly improve a patient’s condition.
Whereas traditional antidepressants can take weeks in the human body before beginning to work, ketamine-based treatments can start to act within 24 hours.
As more is learned about ketamine’s action mechanism, its use is gaining wide wider mainstream acceptance in the clinical setting.
Ketamine is proving to be so successful, that the Food and Drug Administration (the “FDA”) in the United States and Health Canada, its Canadian counterpart, have both fast-tracked approvals for its use in drug discovery and clinical trials.
The evidence for ketamine as a powerful treatment is compelling.
So much so, in fact, that In March 2019 major international pharmaceutical company, Johnson & Johnson, won FDA approval for the first ketamine based psychotherapeutic medicine; Spravato.
Spravato is a nasal spray treatment that has opened the door to the next generation of psychotherapeutic medicines.
For Champignon Brands (CSE:SHRM│OTC:SHRMF), the timing is perfect.
Where Johnson and Johnson relies on a single product to treat a condition as complex as depression, Champignon Brands’ (CSE:SHRM│OTC:SHRMF) visionary team recognized that long-term successful treatment requires a more comprehensive, patient-centred approach.
While Champignon Brands’ (CSE:SHRM│OTC:SHRMF) continue to make great strides in the development of valuable psychotherapeutic medicines, the company’s immediate goal is to establish a network of 5 specialist clinics across New York, California and Florida.
These 5 high-spec treatment centres will put Champignon Brands (CSE:SHRM│OTC:SHRMF) within easy reach of 80 million people.
The company will be the one of the first healthcare provider in North America to provide sufferers of depression with a complete clinical pathway, using the latest psychotherapeutic treatments.
By combining direct clinical care to hundreds of thousands of patients with exciting blockbuster-drug research, Champignon Brands (CSE:SHRM│OTC:SHRMF) is now set to become the global leader in the fight against depression.
This company has billion-dollar potential written all over it.
IMPORTANT NOTICE AND DISCLAIMER
Paid Advertisement
This communication is a paid advertisement. ValueTheMarkets is a trading name of Digitonic Ltd, and its owners, directors, officers, employees, affiliates, agents and assigns (collectively the “Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Champignon Brands Inc to conduct investor awareness advertising and marketing and has paid the Publisher the equivalent of one hundred and sixty-six thousand US dollars to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher’s ability to provide unbiased information or opinion.
Changes in Share Trading and Price
Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur.
No Offer to Sell or Buy Securities
This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security.
Information
Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position.
This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy.
No Financial Advice
The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual’s financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results.
Forward Looking Statements
This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company’s actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company’s operations; the size and growth of the market for the company’s products and services; the company’s ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company’s business.
Indemnification/Release of Liability
By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions.
Terms of Use and Disclaimer
By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here https://www.valuethemarkets.com/terms-conditions/ and acknowledge that you have reviewed the Disclaimer found here https://www.valuethemarkets.com/disclaimer/. If you do not agree to the Terms of Use, please contact ValueTheMarkets.com to discontinue receiving future communications.
Intellectual Property
All trademarks used in this communication are the property of their respective trademark holders. Other than Valuethemarkets.com, the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than Valuethemarkets.com.
Author: Ben Turney
Valuethemarkets.com and Digitonic Ltd and our affiliates are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above.
This article does not provide any financial advice and is not a recommendation to deal in any securities or product. News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance.
Ben Turney does not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. Ben Turney has been paid to produce this piece by the company or companies mentioned above. Digitonic Ltd, the owner of ValueTheMarkets.com, has been paid for the production this piece by the company or companies mentioned above.
